Motley Fool Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.09M | Buy |
167,448
+82,975
| +98% | +$3.02M | 0.28% | 70 |
|
|
2025
Q1 | $3.06M | Buy |
84,473
+36,025
| +74% | +$1.3M | 0.17% | 107 |
|
|
2024
Q4 | $2.04M | Sell |
48,448
-93,201
| -66% | -$3.92M | 0.11% | 136 |
|
|
2024
Q3 | $8M | Buy |
141,649
+360
| +0.3% | +$20.3K | 0.47% | 57 |
|
|
2024
Q2 | $5.81M | Sell |
141,289
-5,237
| -4% | -$215K | 0.39% | 65 |
|
|
2024
Q1 | $6.84M | Sell |
146,526
-2,917
| -2% | -$136K | 0.44% | 63 |
|
|
2023
Q4 | $7.15M | Sell |
149,443
-6,661
| -4% | -$319K | 0.53% | 55 |
|
|
2023
Q3 | $5.57M | Buy |
156,104
+64,416
| +70% | +$2.3M | 0.45% | 59 |
|
|
2023
Q2 | $4.23M | Buy |
91,688
+57,097
| +165% | +$2.63M | 0.38% | 61 |
|
|
2023
Q1 | $1.39M | Sell |
34,591
-2,372
| -6% | -$95.1K | 0.15% | 87 |
|
|
2022
Q4 | $1.71M | Sell |
36,963
-3,151
| -8% | -$146K | 0.19% | 92 |
|
|
2022
Q3 | $1.66M | Sell |
40,114
-42,092
| -51% | -$1.74M | 0.16% | 98 |
|
|
2022
Q2 | $5.25M | Sell |
82,206
-5,631
| -6% | -$359K | 0.49% | 54 |
|
|
2022
Q1 | $6.38M | Sell |
87,837
-32,156
| -27% | -$2.34M | 0.47% | 54 |
|
|
2021
Q4 | $10.1M | Sell |
119,993
-14,364
| -11% | -$1.21M | 0.65% | 48 |
|
|
2021
Q3 | $12.1M | Sell |
134,357
-36,639
| -21% | -$3.3M | 0.79% | 41 |
|
|
2021
Q2 | $16.3M | Buy |
170,996
+18,670
| +12% | +$1.78M | 1.08% | 28 |
|
|
2021
Q1 | $17.3M | Buy |
152,326
+96,990
| +175% | +$11M | 1.25% | 24 |
|
|
2020
Q4 | $7.66M | Buy |
55,336
+9,990
| +22% | +$1.38M | 0.57% | 52 |
|
|
2020
Q3 | $3.89M | Buy |
45,346
+2,997
| +7% | +$257K | 0.35% | 66 |
|
|
2020
Q2 | $3.31M | Buy |
42,349
+13,584
| +47% | +$1.06M | 0.33% | 64 |
|
|
2020
Q1 | $1.28M | Buy |
+28,765
| New | +$1.28M | 0.17% | 89 |
|